Leading pharmaceutical companies Pfizer and Innovent Biologics have signed a major agreement to work together on developing 12 new cancer treatments called antibody-drug conjugates (ADCs). These treatments combine a cancer-killing drug with an antibody that targets cancer cells more precisely, reducing harm to healthy cells. The total value of this partnership could reach $10.5 billion over time. Under the deal, Pfizer will pay Innovent $650 million upfront, with the possibility of paying up to $9.85 billion more if certain milestones are met. Innovent will handle the early stages of development for four of these new treatments, while Pfizer will take charge of future global development and commercialization. Both companies emphasized that their combined expertise will help bring these innovative treatments to patients faster and more effectively worldwide.
Dr. Hui Zhou, Chief Research and Development Officer of Oncology at Innovent, explained, ‘This partnership unites Pfizer’s and Innovent’s top-tier experts to advance new cancer medicines on a global scale. By combining our strengths, we can speed up the development of early-stage cancer treatments and bring innovative therapies to patients more efficiently.’
Jeff Legos, Chief Oncology Officer at Pfizer, added, ‘By joining Innovent’s early research and clinical development with Pfizer’s global research, development, and commercial capabilities, we can strengthen our pipeline and accelerate the delivery of groundbreaking treatments that may change how cancer is treated and improve patients’ lives.’
Once approved, Innovent will also receive payments called royalties based on the sales of these new medicines. The deal is still waiting for regulatory approval before it can be finalized. This agreement follows a similar collaboration between Innovent and Takeda, announced last year, which was also valued at over $10 billion. At that time, Dr. Zhou highlighted the importance of these next-generation cancer drugs, stating that treatments like IBI363 and IBI343 could become breakthrough therapies addressing critical unmet needs in global oncology care.